Sugammadex

Generic Name: Sugammadex

Brand Names: Bridion, Sugammadex Adroiq, Sugammadex Amomed, Sugammadex Fresenius Kabi, Sugammadex Mylan, Sugammadex Piramal

Drug Type: Small Molecule

Chemical Formula: C_₇₂H_₁₁₂O_₄₈S_₈

CAS Number: 343306-71-8

Unique Ingredient Identifier: 361LPM2T56

Background: Sugammadex is a selective relaxant binding agent indicated for reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide during surgery. Rocuronium bromide and vecuronium bromide are neuromuscular blocking medications that cause temporary paralysis and are especially useful for general anesthesia, ventilation, or tracheal intuba...

Indication: Sugammadex is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide or vecuronium bromide in adults and pediatric patients ≥2 years old who are undergoing surgery.

Associated Conditions: Neuromuscular blockade caused by vecuronium bromide

Associated Therapies: -

Clinical Trials

The Impact of Sugammadex on Ileus After Abdominal Wall Reconstruction

Phase 4

Recruiting

Conditions: Ileus
Hernia, Ventral

Interventions: Drug: Neostigmine / Glycopyrrolate
Drug: Sugammadex

First Posted Date: 2023-08-14

Last Posted Date: 2024-01-24

Lead Sponsor: Clayton Petro

Target Recruit Count: 184

Registration Number: NCT05985343

Locations: 🇺🇸
Cleveland Clinic Center for Abdominal Core Health, Cleveland, Ohio, United States

Sugammadex vs Neostigmine/Glycopyrrolate on Urinary Retention After Spine Surgery

Phase 4

Conditions: Spine Surgery
Reversal of Neuromuscular Blockade
Urinary Retention Postoperative

Interventions: Drug: Sugammadex
Drug: Neostigmine
Drug: Rocuronium
Drug: Glycopyrrolate

First Posted Date: 2023-06-02

Last Posted Date: 2023-09-29

Lead Sponsor: University of Missouri-Columbia

Target Recruit Count: 118

Registration Number: NCT05887375

Locations: 🇺🇸
University Hospital, Columbia, Missouri, United States

The ED95 Dose of Sugammadex to Reverse Rocuronium-Induced Deep Neuromuscular Block Back to Shallow Neuromuscular Block

Not yet recruiting

Conditions: Anesthesia, General
Deep Neuromuscular Blockade

Interventions: Drug: Sugammadex

First Posted Date: 2023-05-03

Last Posted Date: 2023-08-09

Lead Sponsor: Ankara University

Target Recruit Count: 40

Registration Number: NCT05841316

Evaluating Outcomes in Cardiac Surgery Patients Who Receive Sugammadex vs. Placebo

Phase 3

Recruiting

Conditions: Surgery

Interventions: Drug: Sugammadex
Other: Placebo

First Posted Date: 2023-04-06

Last Posted Date: 2024-04-12

Lead Sponsor: NorthShore University HealthSystem

Target Recruit Count: 175

Registration Number: NCT05801679

Locations: 🇺🇸
NorthShore University HealthSystem, Evanston, Illinois, United States

Postoperative Urinary Retention After Reversal of Neuromuscular Block by Neostigmine Versus Sugammadex

Phase 4

Completed

Conditions: Urinary Retention Postoperative
Laparoscopic Cholecystectomy
Neuromuscular Blockade
Neuromuscular Blocking Agents
Sugammadex
Neostigmine
Physiological Effects of Drugs

Interventions: Drug: Neostigmine
Drug: Sugammadex

First Posted Date: 2023-04-03

Last Posted Date: 2024-10-09

Lead Sponsor: University of Texas Southwestern Medical Center

Target Recruit Count: 235

Registration Number: NCT05794503

Locations: 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States

An Observational Study to Analyze the Prescription Pattern of Sugammadex and Its Effectiveness and Safety

Recruiting

Conditions: Postoperative Complications
Neuromuscular Blockade
Anesthesia

First Posted Date: 2023-03-29

Last Posted Date: 2024-04-02

Lead Sponsor: Boryung Pharmaceutical Co., Ltd

Target Recruit Count: 7000

Registration Number: NCT05788718

Locations: 🇰🇷
Korea University Anam Hospital, Seoul, Seongbuk-gu, Korea, Republic of

Incidence of Postoperative Residual Neuromuscular Blockade in the Era of Sugammadex

Recruiting

Conditions: Postoperative Residual Curarization

First Posted Date: 2023-03-08

Last Posted Date: 2023-04-14

Lead Sponsor: Seoul National University Hospital

Target Recruit Count: 52

Registration Number: NCT05760560

Locations: 🇰🇷
Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea, Republic of

Effectiveness on Smooth Extubation According to the Administration Time of Sugammadex

Not Applicable

Not yet recruiting

Conditions: Extubation
Sugammadex
Smooth Emergence

Interventions: Drug: sugammadex

First Posted Date: 2023-03-02

Last Posted Date: 2024-07-25

Lead Sponsor: Ajou University School of Medicine

Target Recruit Count: 66

Registration Number: NCT05751603

Diaphragm Function After Reversal of Rocuronium-induced Neuromuscular Blockade With Sugammadex or Neostigmine in Children

Not Applicable

Recruiting

Conditions: Neuromuscular Block, Residual

Interventions: Drug: Neostigmine
Drug: Sugammadex

First Posted Date: 2023-02-13

Last Posted Date: 2023-04-24

Lead Sponsor: Seoul National University Hospital

Target Recruit Count: 82

Registration Number: NCT05724550

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Jongrogu, Korea, Republic of

Low Dose of Sugammadex vs Neostigmine and Glycopyrrolate for the Reversal of Rocuronium

Phase 4

Completed

Conditions: Neuromuscular Blockade

Interventions: Drug: Sugammadex
Drug: Neostigmine and glycopyrrolate

First Posted Date: 2023-02-08

Last Posted Date: 2024-02-20

Lead Sponsor: Ciusss de L'Est de l'Île de Montréal

Target Recruit Count: 144

Registration Number: NCT05718934

Locations: 🇨🇦
CIUSSS de l'Est de l'Ile de Montreal, Montreal, Quebec, Canada

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy